Status:
RECRUITING
Vapocoolant Spray to Reduce Pain With Nexplanon Insertion
Lead Sponsor:
Queen's Medical Center
Collaborating Sponsors:
Lakshmi Devi and Devraj Sharma Endowment
Conditions:
Reducing Pain With Nexplanon Implant Insertion
Eligibility:
FEMALE
14+ years
Phase:
NA
Brief Summary
The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.
Detailed Description
This study will be for patients in the office having a Nexplanon (etonogestrel implant) insertion. The doctor in clinic will evaluate if a patient meets eligibility criteria for this study. If the pat...
Eligibility Criteria
Inclusion
- At least 14 years or older
- Undergoing an etonogestrel implant insertion in the arm in POB1 Suite 1004 or POB2 Suite 402
- English speaking
- Able and willing to sign the informed consent form and agree to terms of the study
Exclusion
- Required or requested narcotics, anxiolytics, IV sedation, or general anesthesia for the procedure
- Known previous exposure to vapocoolant spray
- Nexplanon removal and reinsertion same day during visit in the same arm
- Contraindications to vapocoolant spray components (ethyl chloride and 1,1,1,3,3-pentafluoropropane/1,1,1,2-tetrafluroethane)
- Unable to provide written, informed consent in English
Key Trial Info
Start Date :
June 16 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06933381
Start Date
June 16 2025
End Date
May 1 2026
Last Update
January 9 2026
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Queens Medical Center POB 2 Suite 402
Honolulu, Hawaii, United States, 96813
2
Queens Medical Center POB1 Clinic 1004
Honolulu, Hawaii, United States, 96813
3
Women's Center Queen's North Hawai'i Community Hospital Suite #124 and #120
Waimea, Hawaii, United States, 96743